Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer

[1]  D. McConkey,et al.  A Molecular Inquiry into the Role of Antibody-Drug Conjugates in Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer. , 2021, European urology.

[2]  A. Masson-Lecomte,et al.  European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). , 2021, European urology.

[3]  M. Meng,et al.  Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin , 2021, Clinical Cancer Research.

[4]  D. McConkey,et al.  Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes , 2021, Applied immunohistochemistry & molecular morphology : AIMM.

[5]  R. Golz,et al.  Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer , 2021, Virchows Archiv.

[6]  E. Heath,et al.  The biology and rationale of targeting nectin-4 in urothelial carcinoma , 2020, Nature Reviews Urology.

[7]  N. Ortiz-Brüchle,et al.  Pure high-grade papillary urothelial bladder cancer: a luminal-like subgroup with potential for targeted therapy , 2020, Cellular Oncology.

[8]  D. Bajorin,et al.  Pembrolizumab (pembro) for the treatment of patients with Bacillus Calmette-Guérin (BCG) unresponsive, high-risk (HR) non–muscle-invasive bladder cancer (NMIBC): Over two years follow-up of KEYNOTE-057. , 2020 .

[9]  David C. Smith,et al.  EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Steinberg,et al.  Update on the guideline of guidelines: non‐muscle‐invasive bladder cancer , 2020, BJU international.

[11]  M. Galsky,et al.  Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  F. Markowetz,et al.  Intratumor heterogeneity defines treatment‐resistant HER2+ breast tumors , 2018, bioRxiv.

[13]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[14]  N. Gaisa,et al.  Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications , 2018, Virchows Archiv.

[15]  P. Agarwal,et al.  Current clinical trials in non-muscle invasive bladder cancer. , 2017, Urologic oncology.

[16]  D. Stover,et al.  Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. , 2016, Cancer research.

[17]  Kim K. Emmerton,et al.  Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models. , 2016, Cancer research.

[18]  Sam S. Chang,et al.  Management of carcinoma in situ of the bladder: best practice and recent developments , 2015, Therapeutic advances in urology.

[19]  M. Knowles,et al.  Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity , 2014, Nature Reviews Cancer.

[20]  J. Witjes,et al.  High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. , 2005, Urology.

[21]  D. Slamon,et al.  Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  W. Remmele,et al.  [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. , 1987, Der Pathologe.